Introduction: Stretch of the atrial membrane upregulates the slow component of delayed rectifier K + current (I Ks ). Blockade of angiotensin II subtype 1 receptors (AT 1 R) attenuates this increase in I Ks . The present study aimed to examine the effects of irbesartan, a selective AT 1 R blocker (ABR), on both the enhancement of I Ks and the shortening of action potential duration (APD) induced by stretching atrial myocytes for exploring the mechanisms underlying the prevention of atrial fibrillation (AF) by ABR. Methods: Hyposmotic solution (Hypo-S) was used to stretch guinea pig atrial myocytes. I Ks and APD were recorded using the whole-cell patch-clamp technique. Results: Irbesartan (1-50 μM) attenuated the Hypo-S-induced increase in I Ks and shortening of APD 90 . Hypo-S increased the I Ks by 113.4%, whereas Hypo-S + 1 μM irbesartan and Hypo-S + 50 μM irbesartan increased the I Ks by only 74.5% and 70.3%, respectively. In addition, Hypo-S shortened the APD 90 by 19.0%, whereas Hypo-S + 1 μM irbesartan and Hypo-S + 50 μM irbesartan shortened the APD 90 by 12.1% and 12.0%, respectively. Conclusion: The actions of irbesartan on electrical changes induced by stretching atrial myocytes are associated with blocking AT 1 R. These actions may be beneficial for treating AF.
Introduction
Increasing evidence suggests that the renin-angiotensin system (RAS) is associated with the occurrence of atrial arrhythmias in experimental animals. [1] [2] [3] [4] [5] Recent clinical studies [6] [7] [8] [9] [10] [11] have also suggested that blockade of the RAS with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II (Ang II) type 1 receptor (AT 1 R) blockers is effective for the treatment of atrial fibrillation (AF). However, mechanisms underlying the treatment are not fully understood, especially concerning actions of the drugs on electrical changes in AF.
The shortening of action potential duration (APD) and effective refractory period (ERP) are generally regarded as pivotal factors for the occurrence of reentry-based AF. During AF, impaired atrial contraction causes the atria to dilate or stretch 12, 13 and induce the secretion of Ang II from cardiomyocytes. 14, 15 Zankov et al. demonstrated that both exogenous Ang II and hyposmotic-induced membrane stretch potentiates the slow component of delayed rectifier K + current (I Ks ) in guinea pig myocytes by activating AT 1 R, which results in a shortened atrial APD. These results suggest that the shortening of the atrial APD, associated with I Ks enhancement through the activation of AT 1 R, plays an important role in facilitating the initiation/maintenance of AF. 16, 17 Irbesartan, a selective AT 1 R blocker, was reported to Irbesartan-mediated AT 1 receptor blockade attenuates hyposmotic-induced enhancement of I Ks current and prevents shortening of action potential duration in atrial myocytes inhibit heterologously expressed KCNQ1/KCNE1 (encoding I Ks ) channels, 18 which may contribute to its anti-AF mechanism. However, the effective concentrations of the drug for blocking KCNQ1/KCNE1 channels are far greater than the clinical therapeutic levels achieved in blood. 19, 20 In the present study, we examined the effects of irbesartan on both the increase in I Ks and the shortening of APD induced by hyposmotic solution (Hypo-S) in guinea pig atrial myocytes. The results show that the actions of the drug at therapeutically relevant concentrations on electrical changes induced by the stretching of the atrial cell membrane are, at least partially, associated with blocking AT 1 R and therefore beneficial for AF prevention.
Materials and methods

Isolation of guinea pig atrial myocytes
The experimental procedures were conducted in accordance with the guidelines established by the Animal Care and Use Committee of Shiga University of Medical Science (Shiga, Japan). Single atrial myocytes were enzymatically dissociated from the hearts of non-pregnant adult female Hartley guinea pigs (weighing 250-350 g) using a retrograde Langendorff perfusion method as previously described. 16 
Solutions and chemicals
Normal Tyrode solution (140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl 2 , 0.5 mM MgCl 2 , 0.33 mM NaH 2 PO 4 , 5.5 mM glucose, and 5.0 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH adjusted to 7.4 with NaOH) was used as "isosmotic" extracellular solution (Iso-S, average osmolality: ~285 mOsm/kg). "Hyposmotic" extracellular solution (Hypo-S, average osmolality: ~212 mOsm/kg) was prepared by simply reducing the NaCl concentration to 100 mM in the normal Tyrode solution as previously described. 17 The pipette solution contained 70 mM potassium aspartate, 50 mM KCl, 10 mM KH 2 PO 4 , 1 mM MgSO 4 , 3 mM Na 2 -ATP (Sigma), 0.1 mM Li 2 -GTP (Roche Diagnostics GmbH, Mannheim, Germany), 5 mM ethylene glycol tetraacetic acid (EGTA), and 5 mM HEPES, with the pH adjusted to 7.2 with KOH. Irbesartan (Dainippon Sumitomo Pharma Co., Ltd, Osaka, Japan) was dissolved in dimethyl sulfoxide (DMSO, Sigma) to yield 50 mM stock solution and diluted with Iso-S or Hypo-S to concentrations of 1 and 50 μM, respectively. The concentration of DMSO in the final solution (< 0.1%, V/V) slightly increased (< 3.8%) the osmolality of 50 μM irbesartan + Hypo-S (or Iso-S), but had no effect on cell swelling (see Supplementary Materials) or I Ks .
Electrophysiological recordings and data analysis
Single atrial myocytes were either current-or voltageclamped using the standard whole-cell patch-clamp technique with an EPC-8 patch-clamp amplifier (HEKA Electronics, Lambrecht, Germany). Data were low-pass filtered at 5 kHz, acquired at 2 kHz through a LIH-1600 analogue-to-digital converter (HEKA), and stored on a hard drive using PATCHMASTER software (HEKA). Borosilicate glass electrodes had a tip resistance of 2.5-4.0 MΩ when filled with the pipette solution. All experiments were performed at 36 ± 1°C. I Ks was elicited by depolarizing voltageclamp steps given from a holding potential of −50 mV to various test potentials, under conditions that the Na + current was inactivated by setting the holding potential to −50 mV. The L-type Ca 2+ channel current (I Ca,L ) and the rapid component of delayed rectifier K + current (I Kr ) were blocked by 0.4 μmol/l nisoldipine (Bayer AG, Wuppertal-Elberfeld, Germany) and 0.5 μmol/l dofetilide (Sigma Chemical Co., MO, USA) added to the extracellular solution, respectively.
Variations of I Ks amplitude and the time course of the I Ks were determined by measuring the amplitude of tail currents elicited on repolarization to a holding potential of −50 mV following two seconds (s) of depolarization to +30 mV every 10 s. Voltage-dependence of I Ks activation was evaluated by fitting the I-V relation of the tail currents to a Boltzmann equation as follows:
tail is the tail current amplitude, V h is the voltage at half-maximal activation, V m is the test potential, and k is the slope factor. The deactivation kinetics of I Ks was determined by fitting a single exponential function to the tail current trace. Cell membrane capacitance (C m ) was calculated on the basis of the capacitive transients during 20 ms voltage-clamp steps (± 5 mV), using the equation C m = τ C I 0 /ΔV m (1-I ss /I 0 ), where τ C is the time constant of the capacitive transient, I 0 is the initial peak current amplitude, I ss is the steady-state current value, and ΔV m is the amplitude of the voltage step (5 mV).
Action potentials were evoked in current-clamp mode at a rate of 0.2 Hz by suprathreshold current pulses of 2 ms duration applied through the patch electrode. The APD was measured at 90% repolarization (APD 90 ).
All of the averaged data are presented as mean ± S.E.M. with the number of experiments shown in parentheses. Statistical comparisons were evaluated using Student's t test or one-way analysis of variance (ANOVA) with Newman-Keuls post-hoc test, as appropriate. A p < 0.05 was considered statistically significant.
Results
Irbesartan does not affect the baseline I Ks but attenuates the Hypo-S-induced I Ks enhancement
Based on the concentration-dependent effect of irbesartan on KCNQ1/KCNE1 channels that was previously reported in a Chinese Hamster Ovary (CHO) expression system, 18 we chose to examine the effects of 1-50 μM irbesartan on I Ks channels in guinea pig atrial myocytes, since 1-50 μM irbesartan are close to the therapeutic concentrations in blood 19, 20 and almost the subthreshold for the inhibition of KCNQ1/ KCNE1 channels. Figure 1 (a) depicts a representative timecourse of atrial tail I Ks during the first and second exposures to Hypo-S that caused mechanical stretch of the cell membrane and induced enhancement of the I Ks . Before the second exposure to Hypo-S, the myocyte was pretreated with irbesartan for five minutes. We found that 1-50 μM irbesartan did not affect the baseline I Ks of guinea pig atrial myocytes (current traces indicated by 1 and 3 in Figure 1(b) ), which was quite similar to that in the CHO expression system. 18 As expected, Hypo-S induced increases in both steady-state and tail I Ks currents (current traces 2 and 4 in Figure 1(b) ).
The myocyte swelling observed in Hypo-S reflects the effect of cell membrane stretching that usually occurs during the early stages of AF 12, 21 and affects various ion transport mechanisms, including the I Ks enhancement in atrial myocytes. 17, 22, 23 while the cells were exposed to Hypo-S. Figure 2 (c) summarizes the percentage increases of tail I Ks of cells in Hypo-S in the absence or presence of 1 and 50 μM irbesartan. The percentage increases in tail I Ks for the control cells and those in the presence of 1 and 50 μM irbesartan were 113.40 ± 9.96% (n = 18), 74.52 ± 8.49% (n = 10), and 70.25 ± 9.34% (n = 16), respectively. Increases in tail I Ks in the presence of irbesartan were significantly lower (p < 0.05) than those in the control (Figure 2(c) ). Figure 2(d) shows the current-voltage relationships for tail I Ks recorded during the superfusion with Iso-S (filled circles), Hypo-S (open circles), or Hypo-S + 1 μM irbesartan (open squares). The voltages for half-activation of tail I Ks (V h ) were obtained by fitting the data to the Boltzmann equation and were 9.06 ± 1.28 mV (n = 22) in Iso-S, 2.08 ± 1.29 mV in Hypo-S (n = 13; p < 0.01 vs. Iso-S), and 2.10 ± 1.70 mV in Hypo-S + 1 μM irbesartan (n = 10; p < 0.05 vs. Iso-S), respectively. The Hypo-S caused a significant negative shift of V h ; however, irbesartan did not recover this negative shift in the activation gate. In addition, there were no significant differences in the parameters governing gating kinetics, irrespective of irbesartan treatment. (1) and during first exposure to Hypo-S (2). After washout with normal Tyrode and pretreatment with 1 μM irbesartan for five minutes (3), the same atrial myocyte was exposed to Hypo-S again (4). The dashed line indicates the zero current level. I Ks : delayed rectifier K + current. Table 1 summarizes the effects of 1 μM irbesartan on the deactivation time course of tail I Ks at four different test potentials. The Hypo-S significantly (p < 0.05) slowed the deactivation time course of tail I Ks at voltages between −60 mV and −30 mV. There were, however, no significant differences in the increase of τ values (in parentheses) irrespective of irbesartan treatment, though there was a trend in the irbesartan-induced reduction of the Hypo-S effects on I Ks deactivation. Figure 3 (a-c) shows the superimposed traces of guinea pig atrial action potentials in Iso-S and Hypo-S-(control, Figure 3(a) ), Iso-S and Hypo-S + 1μM irbesartan-( Figure  3(b) ), and Iso-S and Hypo-S + 50 μM (Figure 3(c) ) irbesartan-treated myocytes, respectively. As the bar graphs summarize in Figure 3(d) , Hypo-S shortened the APD 90 by 19.03 ± 1.36 (n = 17), whereas Hypo-S + 1 μM irbesartan shortened the APD 90 by only 12.05 ± 1.38 (n = 9; p < 0.01 vs. Hypo-S) and Hypo-S + 50 μM irbesartan shortened the APD 90 by 12.00 ± 1.46 (n = 14; p < 0.01 vs. Hypo-S). Together, these results suggest that 1-50 μM irbesartan significantly attenuated the Hypo-S-induced shortening of action potentials in atrial myocytes. In addition, no difference in depolarized resting membrane potentials caused by Hypo-S was observed between control cells and those in the presence of irbesartan (data not shown). 
Irbesartan attenuates Hypo-S-induced shortening of the action potential
Discussion
Cellular electrophysiological studies have indicated that the most important impact of AF on ion channels is the marked reduction in inward I Ca,L currents, 12 which leads to atrial contractile dysfunction and induces increased membrane stretching of outward I Ks currents. 17, 21, 22, 24 Changes in both I Ca,L and I Ks contribute to the atrial APD shortening and the loss of its physiological rate adaptation, which promotes atrial electrical and structural remodeling and creates a substrate for persistent AF. 12, 23 In the present study, we found that irbesartan attenuated the stretch-induced enhancement of I Ks , suggesting that the drug possesses the ability to improve the pathophysiological conditions precipitating AF. This hypothesis is supported by the recent identification of KCNQ1 (encoding the α-subunit of the I Ks channel) S140G and R14C mutations in familial AF cases, in which both "gainof-function" mutations cause an enhancement of I Ks . 25, 26 In addition, atrial membrane stretching results in an increase of I Ks -mediated shortening of the atrial APD, which may facilitate the maintenance of AF. 17, 27, 28 Irbesartan can rescue shortening of the APD that is induced by cell membrane stretching. Thus, the inhibition of extreme APD shortening as a result of atrial membrane stretching is involved in the mechanism underlying irbesartan-mediated AF prevention.
Evidence suggests that the RAS plays a pivotal role in the occurrence and maintenance of AF. Atrial membrane stretching during AF not only activates AT 1 R, 29, 30 but also induces the secretion of Ang II from cardiomyocytes. 14, 15 Madrid and colleagues 31 reported that irbesartan in combination with amiodarone was more effective at preventing the recurrence of AF than amiodarone alone. Several recent clinical reports [6] [7] [8] [9] [10] and animal experiments 2,32 have also confirmed the effect of AT 1 R blockers on AF. In the present study, therapeutically relevant concentrations of irbesartan attenuated the stretch-induced increase, but not baseline, levels of atrial I Ks , suggesting that the action of the drug on electrical changes is associated with blocking AT 1 R. This result is consistent with a previous study 33 that found that irbesartan prevented the arrhythmogenic effect of Ang II by blocking AT 1 R in human atrial myocardium. Zankov et al. reported that the selective AT 1 R blockers valsartan and candesartan attenuate Ang II-and stretch-induced enhancement of I Ks and shortening of APD, respectively, by activating AT 1 R in guinea pig atrial myocytes. 16, 17 Based on these previous findings together with the observations of irbesartan in this study, we conclude that the actions of ARBs on electrical changes associated with the dilation or stretch of the atria are involved in the AT 1 R blockade and are beneficial for the prevention of acute electrical remodeling during AF.
In the present study, we also found that Hypo-S depolarized resting membrane potentials in guinea pig myocytes.
Since the inward rectifier current I K1 is responsible for maintaining the resting membrane potential, 23 and irbesartan did not affect the depolarization of the resting membrane potential caused by atrial membrane stretching, we postulate that I K1 is not the therapeutic target of AT 1 R blockers during AF. 34 This lack of effect on the resting membrane potential was also observed with candesartan in a previous study. 17
Conclusions
Irbesartan-mediated AT 1 R blockade attenuates the electrical changes induced by stretching atrial myocytes. This is likely why AF patients derive a pronounced benefit with ABRs such as irbesartan.
